Two Sigma Advisers LP Lowers Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Two Sigma Advisers LP reduced its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 22.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 889,700 shares of the company's stock after selling 259,700 shares during the period. Two Sigma Advisers LP owned about 1.25% of Zentalis Pharmaceuticals worth $2,696,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. State of Wyoming raised its position in shares of Zentalis Pharmaceuticals by 124.6% during the 4th quarter. State of Wyoming now owns 34,716 shares of the company's stock worth $105,000 after purchasing an additional 19,262 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter worth approximately $52,000. Nuveen Asset Management LLC raised its holdings in shares of Zentalis Pharmaceuticals by 35.2% during the fourth quarter. Nuveen Asset Management LLC now owns 641,407 shares of the company's stock valued at $1,943,000 after acquiring an additional 167,062 shares during the last quarter. Millennium Management LLC lifted its position in shares of Zentalis Pharmaceuticals by 8.1% in the fourth quarter. Millennium Management LLC now owns 957,563 shares of the company's stock valued at $2,901,000 after acquiring an additional 71,477 shares in the last quarter. Finally, Integral Health Asset Management LLC purchased a new position in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $3,182,000.

Zentalis Pharmaceuticals Trading Down 2.8%

Shares of ZNTL traded down $0.04 during mid-day trading on Friday, hitting $1.22. The company's stock had a trading volume of 575,977 shares, compared to its average volume of 1,559,092. Zentalis Pharmaceuticals, Inc. has a 1-year low of $1.01 and a 1-year high of $12.68. The firm has a market capitalization of $87.42 million, a P/E ratio of -0.49 and a beta of 1.81. The firm has a 50-day simple moving average of $1.31 and a 200 day simple moving average of $2.15.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.67). As a group, sell-side analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ZNTL shares. HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Wedbush reissued a "neutral" rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $8.24.

Insider Transactions at Zentalis Pharmaceuticals

In other news, Director Scott Dunseth Myers bought 21,000 shares of the business's stock in a transaction that occurred on Wednesday, April 30th. The stock was purchased at an average price of $1.40 per share, with a total value of $29,400.00. Following the purchase, the director now owns 281,192 shares of the company's stock, valued at $393,668.80. This trade represents a 8.07% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 1.90% of the company's stock.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.